800 - 1100

Product Application details systems.

SYNOLAC® 5085 is a solvent-free low viscosity linear saturated polyester (typical average molecular weight 1500).

SYNOLAC® 5085 is a very compatible low viscosity modifier designed for blending with other

SYNOLAC® 5085 is suitable for use with 2-component acrylic isocyanate or polyester isocyanate systems, high quality stoving systems.

Increase solids content

- Improve flexibility, even at low temperatures
- Improve wetting of pigments and substrates

Viscosity at 25°C, mPa.s (Brookfield, SC4-21/13R, 47 s-1) (ISO 3219)

- Improve adhesion and saltspray resistance
- Improve chemical resistance

Polymer Type

Benefits

Solventborne Polyester

Sales Specifications

Performance

Colour, Gardner scale (ISO 4630)	3 max
Acid value, mg KOH/g (ISO 2114)	3 max
Density / Specific Gravity at 20°C, g/ml	1.06
Hydroxyl Content, %	7.6

Other Characteristics¹

Density / Specific Gravity at 20°C, g/ml	1.06
Hydroxyl Content, %	7.6
Hydroxyl Value, mg KOH/g	250
Solid Content, %	100

Note: Acid value and/or Hydroxyl value quoted relative to solid resin

1 The data provided for these properties are typical values, intended only as guides, and should not be construed as sales specifications

RECOMMENDATIONS FOR USE

SYNOLAC® 5085 will react into the blended system via its high hydroxyl content, and will not compromise durability.

It is suggested that initial evaluations be carried out using SYNOLAC® 5085 at substituted levels of between 5% and 15% of the main binder.

(a) 2-component systems

Formulation Guidelines

When used in combination with other hydroxyl containing resins in 2-component systems, SYNOLAC® 5085 will react with aromatic isocyanates such as Desmodur® L series (1) and aliphatic isocyanates such as Tolonate™ HDB series (2) and Desmodur® N series (1).

SYNOLAC® 5085 can be successfully used (at low levels, 2-3%) in water based systems if it is dispersed into the resin system before neutralisation and addition of water.

Recommended ratios using typical isocyanates would be:

The reaction ratio is calculated from the respective equivalent weight or hydroxyl and isocyanate content of the reactants. The relationship is:

Hydroxyl equivalent weight = $\frac{17 \times 100}{1000}$



Isocyanate equivalent weight =

	on solid resin	as supplied
SYNOLAC® 5085	224	224
Desmodur® N 75 series (1)	191	255
Tolonate™ HDB 75 MX (2)	191	255
Desmodur® L 75 (1)	242	323

(b) stoving systems

When used in combination with other resins in stoving systems, SYNOLAC® 5085 will react with most melamine resins, resin solids ratios of between 70:30 and 85:15 binder to amino are suggested.

SOLUBILITY

SYNOLAC® 5085 is soluble in aromatic hydrocarbons, esters and ketones and insoluble in aliphatic hydrocarbons.

COMPATIBILITY

SYNOLAC® 5085 is compatible with many resins including polyesters, acrylics, isocyanates, melamine, urea and alkyd resins.

Notes: (1) Bayer MaterialScience, (2) Vencorex Chemicals

Product Safety

Please refer to the corresponding Safety Data Sheet.

Storage & **Handling**

SYNOLAC® 5085 should be stored indoors in the original, unopened and undamaged container, in a dry place at a temperature not exceeding 30°C. Exposure to direct sunlight should be avoided. In the above mentioned storage conditions the shelf life of the resin will be 6 months from the shipping date SYNOLAC® 5085 should be stored indoors in the original, unopened and undamaged container,

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade

Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Arkema Coating Resins

420, rue d'Estienne d'Orves 92705 Colombes Cedex - France arkema.com - arkemacoatingresins.com

